GlobeNewswire Inc | Apr 27, 2021 07:00AM EDT

April 27, 2021

MOUNTAIN VIEW, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Truist Securities Life Sciences Summit on May 4, 2021 at 4:20 p.m. EDT. The conference will be held in a virtual meeting format.

A live webcast of the event will be available on the Events and Presentations page in the Investors section of the Companys website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Companys website for 90 days following the presentation.

About IGM Biosciences, Inc.Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of multiple diseases. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact

Argot PartnersDavid Pitts212-600-1902igmbio@argotpartners.com